Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC
NCT06690541
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG:
Lorlatinib 100 mg
Sponsor
Peking University Cancer Hospital & Institute